SACIGOMA: Encapsulated Flavour Effects on Satiety

Sponsor
Instituto de Investigación Hospital Universitario La Paz (Other)
Overall Status
Completed
CT.gov ID
NCT03621358
Collaborator
Creaciones Aromáticas Industriales S.A. (Other)
12
1
3
5.6
2.1

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the satiating effects of different gummies with encapsulated flavour on overweight subjects (BMI ≥25 and <30 kg / m2). Some studies have shown that the contribution of different flavours could reduce food intake. This have made grown the interest of food industry in incorporate these compounds in food and to being able to develop new functional foods into the control of body weight, as well as variables of glucose metabolism and lipid profile, which can contribute to te prevention of cardiovascular diseases.

Condition or Disease Intervention/Treatment Phase
  • Other: Control gummy with free flavour (without encapsulating)
  • Other: Experimental gummy with 50% free/50% encapsulated flavour
  • Other: Experimental gummy with 100% encapsulated flavour
N/A

Detailed Description

A randomized, cross-over and double-blind pilot study with 3 study arms is being performed to evaluate the satiating properties of the encapsulated flavours in different gummies in a group of healthy overweight subjects.

The investigators included 12 participants (6 men and 6 women) between 18 and 55 years (BMI ≥25 and <30 kg / m2). All volunteers will be randomized into 3 study groups, and participants will receive the 3 different study products in order during the 3 experimental phases.

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
Double Blind (Participant and Investigator)
Primary Purpose:
Other
Official Title:
Pilot Study to Evaluate the Satiating Effect Using Different Gummies With Encapsulated Flavours in a Group of Healthy Overweight Subjects
Actual Study Start Date :
Apr 13, 2018
Actual Primary Completion Date :
Apr 27, 2018
Actual Study Completion Date :
Sep 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control Gummy

Control gummy with free flavour (without encapsulating)

Other: Control gummy with free flavour (without encapsulating)
12 g/day (3 gummies)

Experimental: Gummy Variety 1

Experimental gummy with 50% free/50% encapsulated flavour

Other: Experimental gummy with 50% free/50% encapsulated flavour
12 g/day (3 gummies)

Experimental: Gummy Variety 2

Experimental gummy with 100% encapsulated flavour

Other: Experimental gummy with 100% encapsulated flavour
12 g/day (3 gummies)

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline Satiety Hunger Assessment [Day 1, 8, 15]

    Visual Analogue Scale (VAS). 100mm horizontal line anchored at each end with the extremes of the subjective feeling to be quantified. Subjects are instructed to rate the sensation being experienced according to how they define the line. e.g., "not at all hungry" (0mm) and "as hungry as I have ever felt" (100mm). Multiple measures are taken at repeated time intervals described below.

Secondary Outcome Measures

  1. Change from Baseline Blood Hormonal Satiety Markers [Day 1, 8, 15]

    GLP1, Peptide YY, Ghrelin, Leptin, GIP, Peptide C

  2. Amount of food consumed in a "food ad libitum" [Day 1, 8, 15]

    120 min After eating the study product

  3. Total amount of food consumed in 24h [Day 1, 8, 15]

    24h Food Record Method

  4. Change from Baseline Glucose Metabolism Parameters [Day 1, 8, 15]

    Glucose

  5. Change from Baseline Lipid Metabolism Parameters [Day 1, 8, 15]

    Cholesterol, LDL-C, HDL-C, TG

  6. Anthropometric Parameters [Day 1, 8, 15]

    Weight and height will be combined to report BMI in kg/m2

  7. Sensory Perception [Day 1, 8, 15]

    Questionnaire of analysis of sensory perception of the food study product. Five questions that are valued on a scale of 0% to 100% asking about the taste and smell of the study product: desire with which the product is taken, taste, smell, consistency and what wait for effectiveness.

  8. Adverse Effects [Day 1, 8, 15]

    Gastrointestinal Symptoms (Nausea, Diarrhea, Bloating and other disorders)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men and women from 18 to 65 years old.

  • Body Mass Index (BMI) ≥25 and <30 kg/m2.

  • Adequate cultural level and understanding for the clinical trial.

  • Signed informed consent

Exclusion Criteria:
  • Subjects with BMI ≥30 or <25 kg /m2

  • Subjects diagnosed with Diabetes Mellitus.

  • Subjects with dyslipidemia on pharmacological treatment

  • Subjects with hypertension on pharmacological treatment

  • Subjects with established diagnosis of eating disorder

  • Smokers or those subjects with high alcohol consumption (> 2-3 servings/day in men and> 1 serving/day in women (1 serving = 1 glass of wine or 1 bottle of beer)

  • Subjects under pharmacological treatment (except oral contraceptives)

  • Subjects with large weight fluctuations of more than 4 kg or who have undergone in six months a weight loss diet

  • Subjects with sensory problems

  • Subjects with gastrointestinal diseases that affect the digestion or absorption of nutrients

  • Pregnant or breastfeeding women

  • Women with menstrual irregularities (absence of menstrual cycle at least 2 months)

  • Subjects with intense physical activity.

  • Subjects with food allergies to meals included in breakfast, study product or lunch or that reject their consumption

  • Subjects with a diagnosis of celiac disease or a gluten intolerance

Contacts and Locations

Locations

Site City State Country Postal Code
1 La Paz University Hospital Madrid Spain

Sponsors and Collaborators

  • Instituto de Investigación Hospital Universitario La Paz
  • Creaciones Aromáticas Industriales S.A.

Investigators

  • Principal Investigator: Carmen Gómez Candela, MD, PhD, La Paz University Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Instituto de Investigación Hospital Universitario La Paz
ClinicalTrials.gov Identifier:
NCT03621358
Other Study ID Numbers:
  • 5003
First Posted:
Aug 8, 2018
Last Update Posted:
Jan 13, 2022
Last Verified:
Apr 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Instituto de Investigación Hospital Universitario La Paz
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2022